Abstract
A T–cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)–specific T cells boosted peptide–reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide–specific T helper 2 cells directly inhibited MBP–specific T helper 1 cells in vitro through the release of interleukin–10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jerne, N.K. Idiotypic networks and other preconceived ideas. Immunol. Rev. 79, 5–24 (1984).
Cohen, I.R. & Young, D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 12, 105–110 (1991).
Claverie, J.M., Prochnicka-Chalufour, A. & Bougueleret, A. Implications of a Fab-like structure for the T-cell receptor. Immunol. Today 10, 10–14 (1989).
Davis, M.M. & Bjorkman, P.J. T-cell antigen receptor genes and T-cell recognition. Nature 334, 395–402 (1988).
Williams, W.V., Weiner, D.B., Wadsworth, S. & Greene, M.I. The antigen-major histocompatibility complex-T-cell receptor interaction: A structural analysis. Immunol. Rev. 7, 339–344 (1988).
Vandenbark, A.A., Hashim, G.A. & Offner, H. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential. J. Neurosci. Res. 43, 391–402 (1996).
Heber-Katz, E. & Acha-Orbea, H. The V-region disease hypothesis: Evidence from autoimmune encephalomyelitis. Immunol. Today 10, 164–169 (1989).
Lider, O., Reshef, T., Beraud, E., Ben-Nun, A. & Cohen, I.R. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239, 181–183 (1988).
Vandenbark, A.A., Hashim, G. & Offner, H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541–544 (1989).
Offner, H., Hashim, G.A. & Vandenbark, A.A. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251, 430–432 (1991).
Howell, M.D. et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246, 668–670 (1989).
Stevens, D.B., Karpus, W.J., Gould, K.E. & Swanborg, R.H. Studies of Vβ8 T cell receptor peptide treatment in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 37, 123–129 (1991).
Kumar, V. & Sercarz, E.E. The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178, 909–916 (1993).
Gregorian, S.K., Lee, W.P., Doudikian, N. & Amento, E.P. Two distinct T cell receptor peptides independently regulate experimental autoimmune neuritis. Am. Assoc. Immunol. 150, 28A (1993).
Broeren, C.P.M. et al. CDR1 T-cell receptor β-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions. Proc. Natl. Acad. Set. USA 91, 5997–6001 (1994).
Matsumoto, Y., Tsuchida, M., Hanawa, H. & Abo, T. T cell receptor peptide therapy for autoimmune encephalomyelitis: Stronger immunization is necessary for effective vaccination. Cell. Immunol. 153, 468–478 (1994).
Kuhrober, A., Schirmbeck, R. & Reimann, J. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. Eur. J. Immunol. 24, 1172–1180 (1994).
Haqqui, T.M., Qu, X.-M., Ma, J. & Sy, M.S. Immunization with TCR Vβ region peptides completely prevents the induction of collagen induced arthritis. Ninth Int. Cong. Immunol. Abstr. 5014, 845 (1995).
Kotzin, B.L. et al. Preferential T cell receptor Vβ gene usage in myelin basic protein reactive T cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 88, 9161–9165 (1991).
Oksenberg, J.R. et al. Selection of T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68–70 (1993).
Shimonkevitz, R., Murray, R. & Kotzin, B. Characterization of T-cell receptor Vβ usage in the brain of a subject with multiple sclerosis. Ann. N. Y. Acad. Sci. 756, 305–306 (1995).
Bourdette, D.N. et al. Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152, 2510–2519 (1994).
Wucherpfennig, K.W. et al. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 248, 1016–1019 (1990).
Ben-Nun, A. et al. Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals. Proc. Natl. Acad. Sci. USA 88, 2466–2470 (1991).
Vandenbark, A.A., Vainiene, M., Celnik, B., Hashim, G. & Offner, H. TCR peptide therapy decreases the frequency of encephalitogenic T cells in the periphery and the central nervous system. J. Neuroimmunol. 39, 251–260 (1992).
Desquenne-Clark, L., Esch, T.R., Otvos, L. Jr. & Heber-Katz, E. T cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA 88, 7219–7223 (1991).
Chou, Y.K. et al. MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: Comparison with myelin basic protein-specific T cells. J. Neurosci Res. (in the press).
Falcioni, F. et al. Self tolerance to T cell receptor Vβ sequences. J. Exp. Med. 182, 249–254 (1995).
Vandenbark, A.A. [Letter to the editor]. J. Immunol. 153, 910 (1994).
Sant'Angelo, D.B. et al. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity 4, 367–376 (1996).
Voskuhl, R.R. et al. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15, 137–143 (1993).
Chou, Y.K. et al. Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152, 2520–2529 (1994).
Allegretta, M., Nicklas, J.A., Sriram, S. & Albertini, R.J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247, 718–721 (1990).
Vandenbark, A.A. et al. Episodic changes in T cell frequencies to myelin basic protein in patients with multiple sclerosis. Neurology 43, 2416–2417 (1993).
Zhang, J. et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973–984 (1994).
Weiner, H.L. et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321–1324 (1993).
Zhang, J., Medaer, R., Stinissen, P., Hafler, D.A. & Raus, J.C.M. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261, 1451–1454 (1993).
Miller, A., Al-Sabagh, A., Santos, L.M.B., Prabhu-Das, M. & Weiner, H.L. Epitopes of myelin basic protein that trigger TGF-β release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immuno. 151, 7307–7315 (1993).
Karpus, W.J. & Swanborg, R.H. CD4+ suppressor cells inhibit the function of effector cells of EAE through a mechanism involving transforming growth factor-beta. J. Immunol. 146, 1163–1168 (1991).
Swain, S.L. Regulation of the development of distinct subsets of CD4+ T cells. Res. Immunol. 142, 14–22 (1991).
Racke, M.K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180, 1961–1966 (1994).
Kennedy, M.K., Torrance, D.S., Picha, K.S. & Mohler, K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149, 2496–2505 (1992).
Rott, O., Fleischer, B. & Cash, E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24, 1434–1440 (1994).
Poser, C.M. et al. New Diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13, 227–236 (1983).
Diebler, G.E., Boyd, L.F. & Kies, M.W. Enzymatic and nonenzymatic degradation of myelin basic protein. Neurochemistry 9, 1371–1385 (1984).
Scharf, S.J., Griffith, R.L. & Erlich, H.A. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive probes. Hum. Immunol. 30, 190–201 (1991).
Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 26, 1614–1619 (1981).
Kurtzke, J.F. Further notes on disability evaluation in multiple sclerosis with scale modification. Neurology 15, 654–662 (1965).
Hauser, S.L., Dawson, D.M. & Lehrich, J.C. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173–180 (1983).
Goodkin, D.E. et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37, 30–40 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vandenbark, A., Chou, Y., Whitham, R. et al. Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial. Nat Med 2, 1109–1115 (1996). https://doi.org/10.1038/nm1096-1109
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1096-1109
This article is cited by
-
Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis
CNS Drugs (2018)
-
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications
Neurotherapeutics (2016)
-
The Mechanisms and Applications of T Cell Vaccination for Autoimmune Diseases: a Comprehensive Review
Clinical Reviews in Allergy & Immunology (2014)
-
Immunotherapy of Multiple Sclerosis
BioDrugs (2013)
-
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP)
Journal of Neuroinflammation (2012)